Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5930 | M871 |
| Selective galanin GAL2 receptor antagonist (Ki values are 13.1 and 420 nM for GAL2 and GAL1 receptors respectively). Blocks the pro-nociceptive effect of GAL2 receptor agonists. | |
| BCC5931 | AR-M 1896 |
| Selective galanin GAL2 receptor agonist (IC50 values are 1.76 and 879 nM for GAL2 and GAL1 respectively). Also shows moderate affinity for GAL3 receptors (Ki values are 88 and 271 nM for GAL2 and GAL3 respectively). Antiepileptogenic agent; prevents full seizures and postkindling increases in hippocampal excitability. | |
| BCC5932 | Bay 55-9837 |
| Selective VPAC2 receptor agonist (EC50 values are 0.4, 100 and >1000 nM for VPAC2, VPAC1 and PAC1, respectively in a cAMP accumulation assay; IC50 values are 60, 8700 and >10000 nM for VPAC2, VPAC1 and PAC1, respectively in a competition binding assay). Stimulates glucose-dependent insulin secretion in isolated human pancreatic islets. Reduces HIV-1 viral replication and shows cooperative effects when given in conjunction with VPAC1 agonists. | |
| BCC5933 | BIM 187 |
| Bombesin/GRP receptor agonist that reduces food intake following i.p. administration. | |
| BCC5934 | BIM 189 |
| Bombesin antagonist that reduces bombesin-induced satiety. | |
| BCC5935 | Catestatin |
| Non-competitive nicotinic cholinergic antagonist; selectively inhibits nicotinic-stimulated catecholamine secretion from chromaffin cells and noradrenergic neurons (IC50 ~ 200 nM). Blocks nicotinic-induced cationic signaling (IC50 ~ 200 - 250 nM) and inhibits nicotinic-agonist induced desensitization of catecholamine release. Also stimulates mast cell release of histamine via a separate mechanism. | |
| BCC5936 | SB 265610 |
| Potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo. | |
| BCC5937 | SB 258719 hydrochloride |
| Selective 5-HT7 receptor antagonist that displays > 100-fold selectivity over a range of other receptors. Reverses the hypothermic effect of 5-CT in mice following i.p. administration. | |
